Article Menu

Export Article

More by Authors Links

Article Data

  • Views 2165
  • Dowloads 136

Original Research

Open Access

Combined measurement of miRNA-183, HE4, and CA-125 increases diagnostic efficiency for ovarian cancer

  • J. Liang1,4,*,
  • X. Yang2,*,
  • L. Liu3,*,
  • L. Qiao4
  • P. Peng1,4
  • J. Zhou1,2

1Department of TCM Gynaecology, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou

2Cancer Research Institute, Southern Medical University, Guangzhou

3Department of Gynaecology, The Third Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Zhuzhou

4Department of Gynaecology, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou (China)

DOI: 10.31083/j.ejgo.2020.01.4788 Vol.41,Issue 1,February 2020 pp.30-35

Published: 15 February 2020

*Corresponding Author(s): J. Liang E-mail: 303050757@qq.com

PDF (1.17 MB) View Full-text

Abstract

Objective: This study aimed to determine the role of miR-205, miR-182, and miR-183 expression in the serum of ovarian cancer patients in the early diagnosis of ovarian cancer. Materials and Methods: The expression of miR-205, miR-182, miR-183, CA-125, and HE4 was detected in the sera of 101 patients with ovarian cancer, 50 patients with benign ovarian diseases, and 50 healthy volunteers. The results were validated in 98 patients with ovarian cancer, 50 patients with benign ovarian diseases, and 53 healthy volunteers. The expression of miR-205, miR-182, miR-183, CA-125, and HE4 was subjected to ROC analysis and binary logistic regression analysis. Results: The sensitivity of miR-182 and CA-125 was highest (0.901% and 0.832, respectively), but the specificity was low (both 0.27) in the early diagnosis of ovarian cancer. HE4 had the highest specificity in the early diagnosis of ovarian cancer. The sensitivity, specificity, and AUC of HE4 were 0.842, 0.81, and 0.847, respectively. Binary logistic regression analysis showed that three variables were suitable for the diagnostic model: Y=Logit(P)=-5.457+5.365*miR183+0.019*HE4+0.004*CA125. Based on the diagnostic model, ROC analysis showed that the sensitivity, specificity, and AUC were 0.97, 0.85, and 0.951, respectively. Statistical validation showed that the sensitivity, specificity and AUC were 0.941, 0.86, and 0.951, respectively. Conclusion: miR-183 has high specificity and sensitivity in the diagnosis of ovarian cancer. Measurement of miR-183 combined with HE4 and CA-125 is of value for the early diagnosis and evaluation of ovarian cancer.

Keywords

miRNA-183; HE4; CA-125; Ovarian cancer.

Cite and Share

J. Liang,X. Yang,L. Liu,L. Qiao,P. Peng,J. Zhou. Combined measurement of miRNA-183, HE4, and CA-125 increases diagnostic efficiency for ovarian cancer. European Journal of Gynaecological Oncology. 2020. 41(1);30-35.

URL:

https://www.ejgo.net/articles/10.31083/j.ejgo.2020.01.4788

References

[1] Siegel R., Naishadham D., Jemal A.: “Cancer statistics, 2013”. CA Cancer J. Clin., 2013, 63, 11.

[2] Foley O.W., Rauh-Hain J.A., del Carmen M.G.: “Recurrent epithelial ovarian cancer: an update on treatment”. Oncology, 2013, 27, 288.

[3] Hall M., Gourley C., McNeish I., Ledermann J., Gore M., Jayson G., et al.: “Targeted anti-vascular therapies for ovarian cancer: current evidence”. Br. J. Cancer, 2013, 108, 250.

[4] Bian J., Li B., Kou X.J., Liu T.Z., Ming L.: “Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer”. Asian Pac. J. Cancer Prev., 2013, 14, 6241.

[5] Tsujiura M., Ichikawa D., Komatsu S., Shiozaki A., Takeshita H., Kosuga T., et al.: “Circulating microRNAs in plasma of patients with gastric cancers”. Br. J. Cancer, 2010, 102, 1174.

[6] Li B.S., Zhao Y.L., Guo G., Li W., Zhu E.D., Luo X., et al.: “Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection”. PLoS One, 2012, 7, 41629.

[7] Chen H.X., Zhang L., Zhang L.L., Du J., Wang H.Y., Wang B.: “MicroRNA-183 correlates cancer prognosis, regulates cancer prolifer-ation and bufalin sensitivity in epithelial ovarian caner”. Am. J. Transl. Res., 2016, 8, 1748.

[8] Marzec-Kotarska B., Cybulski M., Kotarski J.C., Ronowicz A., Tarkowski R., Polak G., et al.: “Molecular bases of aberrant miR-182 expression in ovarian cancer”. Genes Chromosomes Cancer, 2016, 55, 877.

[9] Niu K., Shen W., Zhang Y., Zhao Y., Lu Y.: “MiR-205 promotes motility of ovarian cancer cells via targeting ZEB1”. Gene, 2015, 574, 330.

[10] Wang L., Zhu M.J., Ren A.M., Wu H.F., Han W.M., Tan R.Y., Tu R.Q.: “A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer”. PLoS One, 2014, 9, 96472.

[11] Wang Y.Q., Guo R.D., Guo R.M., Sheng W., Yin L.R.: “MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas”. J. Cell. Biochem., 2013, 114, 1464.

[12] Zheng H., Zhang L.N., Zhao Y.R., Yang D., Song F.J., Wen Y., et al.: “Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer.”. PLoS One, 2013, 8, e77853.

[13] Xu J., Wu C., Che X., Wang L., Yu D., Zhang T., et al.: “Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis”. Mol Carcinog, 2011, 50, 136.

[14] Zhu W., He J., Chen D., Zhang B., Xu L., Ma H., et al: “Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer”. PloS one, 2014, 9, 87780.

[15] Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al: “Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases”. Cell Res, 2008, 18, 997.

[16] Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., et al: “MicroRNA expression profiles classify human cancers”. Nature, 2005, 435, 834.

[17] Eitan R., Kushnir M., Lithwick-Yanai G., David M.B., Hoshen M., Glezerman M., et al: “Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients”. Gynecol Oncol, 2009, 114, 253.

[18] Sorrentino A., Liu C.G., Addario A., Peschle C., Scambia G., Ferlini C.: “Role of microRNAs in drug-resistant ovarian cancer cells”.Gynecol Oncol, 2008, 111, 478.

[19] Yang N., Kaur S., Volinia S., Greshock J., Lassus H., Hasegawa K., et al: “MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer”. Cancer Res, 2008, 68, 10307.

[20] Fang L., Du W.W., Yang W., Rutnam Z.J., Peng C., Li H., et al: “MiR-93 enhances angiogenesis and metastasis by targeting LATS2”. Cell cycle, 2012, 11, 4352.

[21] Yang M., Chen J., Su F., Yu B., Su F., Lin L., et al.: “Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells”. Mol. Cancer, 2011, 10, 117.

[22] Jacobs I., Bast R.C., Jr.: “The CA 125 tumour-associated antigen: a review of the literature”. Hum. Reprod.,1989, 4, 1.

[23] Kirchhoff C.: “Molecular characterization of epididymal proteins”. Rev. Reprod., 1998, 3, 86.

[24] Hellstrom I., Raycraft J., Hayden-Ledbetter M., Ledbetter J.A, Schummer M., McIntosh M., et al.: “The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma”. Cancer Res., 2003, 63, 3695.

[25] Holcomb K., Vucetic Z., Miller M.C., Knapp R.C.: “Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women”. Am. J. Obstet. Gynecol., 2011, 205, 351.

Submission Turnaround Time

Top